MedTrace Logo

Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney

NCT02474667 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 253

Last updated 2021-06-03

No results posted yet for this study

Summary

The major objective is to demonstrate the safety and efficacy of ANG-3777 in improving graft function and reducing the severity of delayed graft function (DGF) in recipients at high risk of DGF after receiving a deceased donor renal allograft.

Conditions

  • Delayed Graft Function

Interventions

DRUG

ANG-3777

OTHER

Placebo

Sponsors & Collaborators

  • CTI Clinical Trial and Consulting Services

    collaborator OTHER

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • John Neylan, MD · Angion Biomedica

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474667 on ClinicalTrials.gov